William Blair lowered shares of Neumora Therapeutics (NASDAQ:NMRA – Free Report) from an outperform rating to a market ...

Fintel reports that on March 10, 2025, Guggenheim downgraded their outlook for Neumora Therapeutics (NasdaqGS:NMRA) from Buy ...

Fintel reports that on March 7, 2025, Stifel downgraded their outlook for Neumora Therapeutics (NasdaqGS:NMRA) from Buy to ...

Neumora Therapeutics (NASDAQ:NMRA – Get Free Report)‘s stock had its “sector perform” rating reaffirmed by investment ...

KOASTAL-2 and -3 studies optimized based on learnings from KOASTAL-1; topline data expected from KOASTAL-3 in the first quarter of 2026 and -2 in the second quarter of 2026 Topline data from NMRA-511 ...

WATERTOWN, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven clinical and ...

Neumora Therapeutics, Inc. (NMRA – Research Report) received a Hold rating and price target from William Blair analyst Myles Minter ...

William Blair downgraded Neumora Therapeutics (NMRA) to Market Perform from Outperform.Discover the Best Stocks and Maximize Your Portfolio: ...

March 03, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA) a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven brain disease programs ...

Neumora Therapeutics (NMRA) surprised investors in its Q4 2024 earnings call by reporting an earnings per share (EPS) of -$0.37, surpassing the forecasted -$0.62. This unexpected result led to a ...